Screener › Biotech Small Cap Aktien
Biotech Small Cap Aktien
Small und Micro Cap Biotech-Aktien unter 5 Mrd. USD Marktkapitalisierung — Hochrisiko, Hochrendite Pipeline-Plays in Gentherapie, Onkologie, seltenen Erkrankungen und Präzisionsmedizin.
| Ticker | Unternehmen | Kurs | Marktkapitalisierung | Kurspotenzial | 52W Pos. | Smart Money |
|---|---|---|---|---|---|---|
| IMVT | Immunovant | $24.50 -2.39% | $4.99B | 65.7% | 71.3% | — |
| FOLD | Amicus Therapeutics | $14.44 +0% | $4.53B | 0.4% | 99.8% | — |
| NVST | Envista Holdings | $25.81 -0.35% | $4.24B | 11.1% | 71.5% | — |
| MMSI | Merit Medical Systems | $67.70 -0.78% | $4.02B | 50.7% | 4% | — |
| VKTX | Viking Therapeutics | $34.80 +5.58% | $4.02B | 166.4% | 65.5% | — |
| LGND | Ligand Pharmaceuticals | $199.59 -0.02% | $3.98B | 22.8% | 78.9% | — |
| ALHC | Alignment Healthcare | $18.76 +5.1% | $3.83B | 35.9% | 58.3% | — |
| ACAD | Acadia Pharmaceuticals | $22.20 -0.54% | $3.78B | 43.5% | 58.9% | — |
| IRTC | iRhythm Technologies | $116.80 -1.2% | $3.77B | 81% | 20.3% | — |
| STVN | Stevanato Group | $13.73 -0.15% | $3.75B | 83.3% | 5.6% | — |
| FIE.DE | Fielmann | $43.20 -1.26% | $3.63B | 41.8% | 24.2% | — |
| EWTX | Edgewise Therapeutics | $33.33 +0.57% | $3.58B | 23.3% | 99% | — |
| TMDX | TransMedics Group | $100.69 +0.29% | $3.45B | 60.2% | 41% | — |
| SFZN.SW | Siegfried Holding | $77.70 +0% | $3.4B | 34.6% | 50.1% | — |
| DNLI | Denali Therapeutics | $20.65 +4.93% | $3.27B | 75% | 76.4% | — |
| TWST | Twist Bioscience | $50.21 +1.35% | $3.08B | 0.5% | 77.8% | — |
| VIRP.PA | Virbac | $351.00 -0.85% | $2.94B | 17.7% | 81.8% | — |
| ARQT | Arcutis Biotherapeutics | $23.63 -1.95% | $2.93B | 47.1% | 59.1% | — |
| TVTX | Travere Therapeutics | $30.44 -3.12% | $2.81B | 39.6% | 60% | — |
| DMP.DE | Dermapharm Holding | $47.25 +1.72% | $2.54B | -7.9% | 100% | — |
| BEAM | Beam Therapeutics | $24.66 +1.82% | $2.51B | 107.6% | 48.6% | — |
| LMAT | LeMaitre Vascular | $108.49 -0.24% | $2.47B | 2.5% | 84.4% | — |
| SRPT | Sarepta Therapeutics | $23.23 +4.97% | $2.44B | -6.8% | 23.6% | — |
| ZLAB | Zymeworks | $20.41 +0.34% | $2.31B | 88.5% | 15.7% | — |
| NKTR | Nektar Therapeutics | $76.99 +1.69% | $2.21B | 66.4% | 97.5% | — |
| ADMA | ADMA Biologics | $9.19 +0.88% | $2.19B | 155.7% | 10.7% | — |
| CLDX | Celldex Therapeutics | $31.06 -0.64% | $2.07B | 74.9% | 82.8% | — |
| AGIO | Agios Pharmaceuticals | $35.20 +2.95% | $2.06B | 24.3% | 54.5% | — |
| OCUL | Ocular Therapeutix | $8.49 +1.92% | $1.85B | 206.2% | 25.3% | — |
| DVAX | Dynavax Technologies | $15.50 +0% | $1.82B | 3.2% | 50% | — |
| INVA | Innoviva | $22.99 -1.79% | $1.72B | 44.4% | 75% | — |
| TECN.SW | Tecan Group | $135.40 -1.02% | $1.71B | 23.4% | 37.1% | — |
| DRW3.DE | Draegerwerk | $90.40 -0.66% | $1.7B | 6.5% | 85.6% | — |
| ANAB | AnaptysBio | $57.68 +1.67% | $1.66B | 38.5% | 79.8% | — |
| RXRX | Recursion Pharmaceuticals | $3.11 +1.63% | $1.64B | 115.9% | 7.1% | — |
| ATEC | Alphatec Holdings | $10.83 -3.82% | $1.64B | 125.5% | 14% | — |
| OMCL | Omnicell | $34.15 +0.62% | $1.55B | 68.2% | 35.5% | — |
| UFPT | UFP Technologies | $192.02 -1.02% | $1.48B | 69% | 14.2% | — |
| FAE.MC | Faes Farma | $4.70 -0.95% | $1.46B | 12.9% | 61.4% | — |
| ARDX | Ardelyx | $5.94 -2.78% | $1.46B | 171% | 52.6% | — |
| IOVA | Iovance Biotherapeutics | $3.43 -0.58% | $1.41B | 162.4% | 44.9% | — |
| TNDM | Tandem Diabetes Care | $18.61 -1.06% | $1.27B | 65.3% | 43.9% | — |
| NVAX | Novavax | $7.70 -3.99% | $1.25B | 78.9% | 38.6% | — |
| CRVS | Corvus Pharmaceuticals | $14.69 +1.8% | $1.23B | 139.4% | 49.8% | — |
| NVCR | NovoCure | $10.55 -2.68% | $1.2B | 147.1% | 7.1% | — |
| USPH | US Physical Therapy | $73.74 -0.89% | $1.12B | 41% | 35.7% | — |
| CNMD | Conmed Corporation | $34.79 -2.08% | $1.08B | 27.1% | 5.7% | — |
| XNCR | Xencor | $12.81 +2.23% | $939.5M | 121.8% | 50% | — |
| EUZ.DE | Eckert and Ziegler | $14.57 -3.83% | $911.7M | 54% | 12.8% | — |
| OPK | OPKO Health | $1.14 +0.88% | $875.2M | 198.3% | 8% | — |
| INMD | InMode | $13.79 +0.66% | $873.7M | 23.3% | 26.6% | — |
| CERT | Certara | $5.41 -1.64% | $861.7M | 66.1% | 1.7% | — |
| SDGR | Schrodinger | $11.58 +0.26% | $854.9M | 90% | 3.8% | — |
| EVT.DE | Evotec | $4.50 +1.03% | $800.4M | 53.6% | 11.1% | — |
| MNKD | MannKind Corporation | $2.50 -1.57% | $770.3M | 200% | 6.3% | — |
| CBAV.MC | Clinica Baviera | $47.90 -0.21% | $767.3M | — | 67.7% | — |
| CMPS | COMPASS Pathways | $5.79 +3.02% | $746.5M | 275.7% | 53.2% | — |
| PSNL | Personalis | $6.58 +0.3% | $688.5M | 73.7% | 43.3% | — |
| HSTM | HealthStream | $20.45 +0.25% | $606.7M | 49.1% | 6.5% | — |
| EMBC | Embecta Corp | $8.85 +0.68% | $524.1M | 88.3% | 5.4% | — |
| REG1V.HE | Revenio Group | $19.04 -0.1% | $506.6M | 21.1% | 13.5% | — |
| LBIRD.PA | Lumibird | $21.70 -0.46% | $477.9M | 30.9% | 82.9% | — |
| PACB | Pacific Biosciences | $1.34 -0.74% | $404.7M | 92.8% | 26.1% | — |
| WEAV | Weave Communications | $4.91 +3.59% | $386.2M | 78.2% | 9.5% | — |
| FYB.DE | Formycon | $18.62 -1.79% | $329.1M | 118.7% | 18.2% | — |
| CCCC | C4 Therapeutics | $2.82 +4.44% | $275.2M | 310.3% | 63.4% | — |
| EOLS | Evolent Health | $4.03 -6.5% | $262.2M | 263.9% | 2% | — |
| EDIT | Editas Medicine | $2.67 +2.3% | $261.3M | 106% | 48.5% | — |
| PRLD | Prelude Therapeutics | $3.46 +0.29% | $217.5M | 49.3% | 78.9% | — |
| SBS.DE | Stratec | $17.76 +1.49% | $215.9M | 60.3% | 8.4% | — |
| RNA | Avidity Biosciences | $13.44 -0.22% | $208.5M | 86% | 30.9% | — |
| CRBU | Caribou Biosciences | $1.94 -2.51% | $187.5M | 473.5% | 44.5% | — |
| NNOX | Nano-X Imaging | $2.41 +0% | $167.7M | 207.1% | 8% | — |
| VXRT | Vaxart | $0.61 +0% | $147.3M | 391.8% | 60.3% | — |
| FATE | Fate Therapeutics | $1.22 -1.61% | $141.8M | 305.3% | 42.9% | — |
| HYPR | Hyperfine | $1.13 +3.67% | $110.7M | 81.4% | 35.4% | — |
| SEER | Seer Bio | $1.70 +0% | $95.9M | — | 7.8% | — |
| TMCI | Treace Medical Concepts | $1.45 +2.84% | $93.7M | 193.1% | 4% | — |
| AMWL | Amwell | $5.50 +3.97% | $91M | 13.6% | 32.9% | — |
| HCAT | Health Catalyst | $1.17 +0.86% | $86.1M | 67.9% | 3.2% | — |
| CTSO | Cytosorbents Corporation | $0.58 +6.52% | $36.6M | 800.5% | 9.4% | — |
| TELA | Tela Bio | $0.60 +5.01% | $26.7M | 276.7% | 5.7% | — |
| MARI.VI | Marinomed Biotech | $14.30 -0.35% | $26.4M | 253.2% | 28% | — |
Analyse und Kontext
Dieser sektorbezogene Screener zeigt aktuell 83 Aktien aus dem ausgewählten Segment — täglich aktualisiert. Das durchschnittliche KGV liegt bei 26.6x. Das durchschnittliche Umsatzwachstum beträgt 30.9%. Sektoren durchlaufen zyklische Phasen die stark mit makroökonomischen Faktoren korrelieren — Zinsniveau, Wirtschaftswachstum, Rohstoffpreise und regulatorisches Umfeld beeinflussen die Branchendynamik entscheidend. Analysten sehen im Schnitt 105.3% Kurspotenzial in diesen Sektortiteln. Vergleiche die Kennzahlen dieser Aktien mit dem Branchendurchschnitt um relative Über- und Unterbewertungen zu identifizieren. Sektorkonzentration erhöht das Portfoliorisiko — achte auf ausreichende Diversifikation über verschiedene Branchen und Geschäftsmodelle.
Bereit zu investieren?
Vergleiche die besten Broker für deutsche und internationale Aktien — Gebühren, Plattformen und Angebote im Direktvergleich.
Broker vergleichen →